HIV Citation List: January 20 - February 2, 2012

Pubmed citations

1. Mechanism of HIV Antiretroviral Drugs Progress Toward Drug Resistance. Ammaranond, P. and S. Sanguansittianan, Fundamental & Clinical Pharmacology, 2012. 26(1): p. 146-161; PMID[22118474].

[Pubmed]. HIV_0120-020212.

2. Characterization of the Inhibition Mechanism of HIV-1 Nucleocapsid Protein Chaperone Activities by Methylated Oligoribonucleotides. Avilov, S.V., C. Boudier, M. Gottikh, J.L. Darlix, and Y. Mely, Antimicrobial Agents and Chemotherapy, 2012. 56(2): p. 1010-1018; PMID[22083480].
[Pubmed]. HIV_0120-020212.

3. ADAR1 is a Novel Multi Targeted anti-HIV-1 Cellular Protein. Biswas, N., T. Wang, M. Ding, A. Tumne, Y. Chen, Q. Wang, and P. Gupta, Virology, 2012. 422(2): p. 265-277; PMID[22104209].
[Pubmed]. HIV_0120-020212.

4. The HIV-1 Protease Inhibitor Nelfinavir Impairs Proteasome Activity and Inhibits the Multiple Myeloma Cells Proliferation in Vitro and in Vivo. Bono, C., L. Karlin, S. Harel, E. Mouly, S. Labaume, L. Galicier, S. Apcher, H. Sauvageon, J.P. Fermand, J.C. Bories, and B. Arnulf, Haematologica, 2012. [Epub ahead of print]; PMID[22271897].
[Pubmed]. HIV_0120-020212.

5. Baseline Susceptibility of Primary HIV-2 to Entry Inhibitors.. Borrego, P., R. Calado, J.M. Marcelino, I. Bartolo, C. Rocha, P. Cavaco-Silva, M. Doroana, F. Antunes, F. Maltez, U. Caixas, H. Barroso, and N. Taveira, Antiviral Therapy, 2012. [Epub ahead of print]; PMID[22293827].
[Pubmed]. HIV_0120-020212.

6. A Synthetic Heparan Sulfate-mimetic Peptide Conjugated to a Mini CD4 Displays Very High anti-HIV-1 Activity Independently of Coreceptor Usage. Connell, B.J., F. Baleux, Y.M. Coic, P. Clayette, D. Bonnaffe, and H. Lortat-Jacob, Chemistry & Biology, 2012. 19(1): p. 131-139; PMID[22284360].
[Pubmed]. HIV_0120-020212.

7. Cyclic Peptide Inhibitors of HIV-1 Capsid-human Lysyl-tRNA Synthetase Interaction. Dewan, V., T. Liu, K.M. Chen, Z. Qian, M. Niu, L. Kleiman, K. Mahasenan, C. Li, H. Matsuo, D. Pei, and K. Musier-Forsyth, ACS Chemical Biology, 2012. [Epub ahead of print]; PMID[22276994].
[Pubmed]. HIV_0120-020212.

8. The GB Virus C (GBV-C) NS3 Serine Protease Inhibits HIV-1 Replication in a CD4+ T Lymphocyte Cell Line without Decreasing HIV Receptor Expression. George, S.L., D. Varmaz, J.E. Tavis, and A. Chowdhury, Plos One, 2012. 7(1): p. e30653; PMID[22292009].
[Pubmed]. HIV_0120-020212.

9. Inhibition of HIV-1 Protease: The Rigidity Perspective. Heal, J.W., J.E. Jimenez-Roldan, S.A. Wells, R.B. Freedman, and R.A. Romer, Bioinformatics, 2012. 28(3): p. 350-357; PMID[22291339].
[Pubmed]. HIV_0120-020212.

10. Synthesis and Biological Evaluation of Deoxy-hematoxylin Derivatives as a Novel Class of anti-HIV-1 Agents. Ishii, H., H. Koyama, K. Hagiwara, T. Miura, G. Xue, Y. Hashimoto, G. Kitahara, Y. Aida, and M. Suzuki, Bioorganic & Medicinal Chemistry Letters, 2012. 22(3): p. 1469-1474; PMID[22244940].
[Pubmed]. HIV_0120-020212.

11. Origin of Decrease in Potency of Darunavir and Two Related Antiviral Inhibitors against HIV2 Compared to HIV1 Protease. Kar, P. and V. Knecht, The Journal of Physical Chemistry B, 2012. [Epub ahead of print]; PMID[22280246].
[Pubmed]. HIV_0120-020212.

12. Pentacycloundecane Derived Hydroxy acid Peptides: A New Class of Irreversible Non-scissile Ether Bridged Type Isoster as Potential HIV-1 Wild Type C-SA Protease Inhibitors. Karpoormath, R., Y. Sayed, P. Govender, T. Govender, H.G. Kruger, M.E. Soliman, and G.E. Maguire, Bioorganic Chemistry, 2012. 40(1): p. 19-29; PMID[21982718].
[Pubmed]. HIV_0120-020212.

13. Strategies for The Design of HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors: Lessons from The Development of Seven Representative Paradigms. Li, D., P. Zhan, E. De Clercq, and X. Liu, Journal of Medicinal Chemistry, 2012. [Epub ahead of print]; PMID[22268494].
[Pubmed]. HIV_0120-020212.

14. Effect of the HIV Nucleoside Reverse Transcriptase Inhibitor Zidovudine on the Growth and Differentiation of Primary Gingival Epithelium. Mitchell, D., M. Israr, S. Alam, J. Kishel, D. Dinello, and C. Meyers, HIV Medicine, 2012. [Epub ahead of print]; PMID[22276657].
[Pubmed]. HIV_0120-020212.

15. Testing of Viscous anti-HIV Microbicides Using Lactobacillus. Moncla, B.J., K. Pryke, L.C. Rohan, and H. Yang, Journal of Microbiological Methods, 2012. 88(2): p. 292-296; PMID[22226641].
[Pubmed]. HIV_0120-020212.

16. Anti-Human Immunodeficiency Virus Type 1 Activity of Novel 6-Substituted 1-benzyl-3-(3,5-dimethylbenzyl)uracil derivatives. Ordonez, P., T. Hamasaki, Y. Isono, N. Sakakibara, M. Ikejiri, T. Maruyama, and M. Baba, Antimicrobial Agents and Chemotherapy, 2012. [Epub ahead of print]; PMID[22290950].
[Pubmed]. HIV_0120-020212.

17. Development and Performance of Conventional HIV-1 Phenotyping (Antivirogram(R)) and Genotype-based Calculated Phenotyping Assay (virco(R)TYPE HIV-1) on Protease and Reverse Transcriptase Genes to Evaluate Drug Resistance. Pattery, T., Y. Verlinden, H. De Wolf, D. Nauwelaers, K. Van Baelen, M. Van Houtte, P. Mc Kenna, and J. Villacian, Intervirology, 2012. 55(2): p. 138-146; PMID[22286884].

[Pubmed]. HIV_0120-020212.

18. Development of Novel CXCR4-based Therapeutics. Peled, A., O. Wald, and J. Burger, Expert Opinion on Investigational Drugs, 2012. [Epub ahead of print]; PMID[22283809].
[Pubmed]. HIV_0120-020212.

19. Drug Interaction Profile for GSK2248761, a Next-generation Non-nucleoside Reverse Transcriptase Inhibitor. Piscitelli, S., J. Kim, E. Gould, Y. Lou, S. White, M. de Serres, M. Johnson, X.J. Zhou, K. Pietropaolo, and D. Mayers, British Journal of Clinical Pharmacology, 2012. [Epub ahead of print]; PMID[22288567].
[Pubmed]. HIV_0120-020212.

20. Cytosine Deoxyribonucleoside anti-HIV Analogues: A Small Chemical Substitution Allows Relevant Activities. Scaglione, F. and L. Berrino, International Journal of Antimicrobial Agents, 2012. [Epub ahead of print]; PMID[22269860].
[Pubmed]. HIV_0120-020212.

21. In Vitro Resistance Profile of the Candidate HIV-1 Microbicide Drug Dapivirine. Schader, S.M., M. Oliveira, R.I. Ibanescu, D. Moisi, S.P. Colby-Germinario, and M.A. Wainberg, Antimicrobial Agents and Chemotherapy, 2012. 56(2): p. 751-756; PMID[22123692].
[Pubmed]. HIV_0120-020212.

22. Characterization of an HIV-Targeted Transcriptional Gene-silencing RNA in Primary Cells. Turner, A.M., A.M. Ackley, M.A. Matrone, and K.V. Morris, Human Gene Therapy, 2012. [Epub ahead of print]; PMID[22122263].
[Pubmed]. HIV_0120-020212.

23. A Novel High-throughput Cellular Screening Assay for the Discovery of HIV-1 Integrase Inhibitors. Van Loock, M., G. Meersseman, K. Van Acker, C. Van Den Eynde, D. Jochmans, B. Van Schoubroeck, G. Dams, L. Heyndrickx, and R.F. Clayton, Journal of Virological Methods, 2012. 179(2): p. 396-401; PMID[22172974].
[Pubmed]. HIV_0120-020212.

24. Design, Synthesis and Biological Evaluation of 1-[(2-Benzyloxyl/alkoxyl) methyl]-5-halo-6-aryluracils as Potent HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors with Improved Drug Resistance Profile. Wang, X., J. Zhang, Y. Huang, R. Wang, L. Zhang, K. Qiao, L. Li, C. Liu, Y. Ouyang, W. Xu, Z. Zhang, Y. Shao, S. Jiang, L. Ma, and J. Liu, Journal of Medicinal Chemistry, 2012. [Epub ahead of print]; PMID[22283377].
[Pubmed]. HIV_0120-020212.

25. Synthesis and Antiviral Activities of Novel Gossypol Derivatives. Yang, J., F. Zhang, J. Li, G. Chen, S. Wu, W. Ouyang, W. Pan, R. Yu, and P. Tien, Bioorganic & Medicinal Chemistry Letters, 2012. 22(3): p. 1415-1420; PMID[22226654].
[Pubmed]. HIV_0120-020212.

26. Broad Antiviral Activity and Crystal Structure of HIV-1 Fusion Inhibitor Sifuvirtide. Yao, X., H. Chong, C. Zhang, S. Waltersperger, M. Wang, S. Cui, and Y. He, Journal of Biological Chemistry, 2012. [Epub ahead of print]; PMID[22228771].
[Pubmed]. HIV_0120-020212.

27. Facile Synthesis of Acacetin-7-O-beta-D-galactopyranoside. Zacharia, J.T. and M. Hayashi, Carbohydrate Research, 2012. 348: p. 91-94; PMID[22226544].
[Pubmed]. HIV_0120-020212.

28. Bicyclic Hydroxy-1H-pyrrolopyridine-trione Containing HIV-1 Integrase Inhibitors. Zhao, X.Z., K. Maddali, M. Metifiot, S.J. Smith, B.C. Vu, C. Marchand, S.H. Hughes, Y. Pommier, and T.R. Burke, Jr., Chemical Biology & Drug Design, 2012. 79(2): p. 157-165; PMID[22107736].
[Pubmed]. HIV_0120-020212.

ISI Web of Knowledge citations

29. Evaluation of the Performance of the Abbott ARCHITECT HIV Ag/Ab Combo Assay. Chavez, P., L. Wesolowski, P. Patel, K. Delaney, and S.M. Owen, Journal of Clinical Virology, 2011. 52: p. S51-S55; ISI[000298149500011].
[WOS]. HIV_0120-020212.

30. Iron Chelators of the di-2-Pyridylketone thiosemicarbazone and 2-Benzoylpyridine thiosemicarbazone Series Inhibit HIV-1 Transcription: Identification of Novel Cellular Targets-Iron, Cyclin-Dependent Kinase (CDK) 2, and CDK9. Debebe, Z., T. Ammosova, D. Breuer, D.B. Lovejoy, D.S. Kalinowski, K. Kumar, M. Jerebtsova, P. Ray, F. Kashanchi, V.R. Gordeuk, D.R. Richardson, and S. Nekhai, Molecular Pharmacology, 2011. 80(6): p. 1190-1190; ISI[000298414200023].
[WOS]. HIV_0120-020212.

31. 1,3,4-Oxadiazole: A Privileged Structure in Antiviral Agents. Li, Z., P. Zhan, and X. Liu, Mini-Reviews in Medicinal Chemistry, 2011. 11(13): p. 1130-1142; ISI[000298498000004].
[WOS]. HIV_0120-020212.

32. Introducing Catastrophe-QSAR. Application on Modeling Molecular Mechanisms of Pyridinone Derivative-Type HIV Non-nucleoside Reverse Transcriptase Inhibitors. Putz, M.V., M. Lazea, A.M. Putz, and C. Duda-Seiman, International Journal of Molecular Sciences, 2011. 12(12): p. 9533-9569; ISI[000298405100075].
[WOS]. HIV_0120-020212.

33. TRAF6 and IRF7 Control HIV Replication in Macrophages. Sirois, M., L. Robitaille, R. Allary, M. Shah, C.H. Woelk, J. Estaquier, and J. Corbeil, Plos One, 2011. 6(11); ISI[000298163400033].
[WOS]. HIV_0120-020212.

34. An Ethnobotanical Survey of Medicinal Plants of Laos Toward the Discovery of Bioactive Compounds as Potential Candidates for Pharmaceutical Development. Soejarto, D.D., C. Gyllenhaal, M.R. Kadushin, B. Southavong, K. Sydara, S. Bouamanivong, M. Xaiveu, H.J. Zhang, S.G. Franzblau, G.T. Tan, J.M. Pezzuto, M.C. Riley, B.G. Elkington, and D.P. Waller, Pharmaceutical Biology, 2012. 50(1): p. 42-60; ISI[000298380200007].
[WOS]. HIV_0120-020212.

35. Transcriptional Gene Silencing of HIV-1 Through Promoter Targeted RNA is Highly Specific. Suzuki, K., T. Ishida, M. Yamagishi, C. Ahlenstiel, S. Swaminathan, K. Marks, D. Murray, E.M. McCartney, M.R. Beard, M. Alexander, D.F.J. Purcell, D.A. Cooper, T. Watanabe, and A.D. Kelleher, RNA Biology, 2011. 8(6): p. 1035-1046; ISI[000298630600013].
[WOS]. HIV_0120-020212.

36. Single-Chain Fv-Based anti-HIV Proteins: Potential and Limitations. West, A.P., R.P. Galimidi, P.N.P. Gnanapragasam, and P.J. Bjorkman, Journal of Virology, 2012. 86(1): p. 195-202; ISI[000298347700019].
[WOS]. HIV_0120-020212.

37. HIV-1 Glycoprotein 41 Ectodomain Induces Activation of the CD74 Protein-mediated Extracellular Signal-regulated Kinase/Mitogen-activated Protein Kinase Pathway to Enhance Viral Infection. Zhou, C., L. Lu, S.Y. Tan, S.B. Jiang, and Y.H. Chen, Journal of Biological Chemistry, 2011. 286(52): p. 44869-44877; ISI[000298645500055].
[WOS]. HIV_0120-020212.

38. Current Progress in the Development of RNAi-based Therapeutics for HIV-1. Zhou, J. and J.J. Rossi, Gene Therapy, 2011. 18(12): p. 1134-1138; ISI[000298345500006].
[WOS]. HIV_0120-020212.

SciFinder citations

39. 2-(Quinolin-6-yl)acetic acid Derivatives as HIV Antiviral Agents and Their Preparation and Use for the Treatment of AIDS. Babaoglu, K., K. Bjornson, H. Guo, R.L. Halcomb, J.O. Link, H. Liu, M.L. Mitchell, J. Sun, R.W. Vivian, and L. Xu. 2012: 351pp.

[SciFinder]. HIV_0120-020212.

40. 2-(Naphth-2-yl)acetic acid Derivatives as HIV Antiviral Agents and Their Preparation and Use for the Treatment of AIDS. Babaoglu, K., K. Bjornson, H. Guo, R.L. Halcomb, J.O. Link, R. McFadden, M.L. Mitchell, P. Roethle, J.D. Trenkle, R.W. Vivian, and L. Xu. 2012: 2011-US42880 2012003497: 444pp..

[SciFinder]. HIV_0120-020212.

41. Anti-Hiv Infection Polypeptides, Composition, and Use. Liu, K., S. Jiang, W. Shi, Q. Jia, Y. Bai, S. Feng, L. Cai, C. Wang, S. Zhang, and X. Jiang. 2012: 2011-CN76812 2012000459: 31pp.

[SciFinder]. HIV_0120-020212.

42. N2, N4-Bis-Substituted-2h,4h-pyrrolo[1,2-B][1,2,4,6]thiophene-triazine-1,1,3-trione Derivatives, Their Preparation Method and Application as HIV-1 Non-nucleoside Inhibitors to Prepare anti-HIV Drugs. Liu, X., W. Chen, and P. Zhan. 2012: 2011-10202340 102321102: 20pp.

[SciFinder]. HIV_0120-020212.

43. Analogs of 2',3'-Dideoxy-3'-fluorothymidine 5'-monophosphate for Treatment of HIV Infection. Miazga, A., P. Ziemkowski, T. Kulikowski, F. Hamy, S. Louvel, and T. Klimkait. 2012: 2010-172852 2402357: 10pp.

[SciFinder]. HIV_0120-020212.

44. Aroylhydrazone Derivatives, Their Preparation and Application in Preparing anti-HIV-1 Drugs. Xu, H. and Z. Che. 2012: 2011-10192240 102321009: 24pp.

[SciFinder]. HIV_0120-020212.

45. Modified 2',3'-Dideoxynucleosides for Treatment Infections Caused by HIV. Ziemkowski, P., A. Miazga, T. Kulikowski, T. Klimkait, S. Louvel, F. Hamy, A. Lipniacki, and A. Piasek. 2012: 2010-172854

2402356: 8pp.

[SciFinder]. HIV_0120-020212.

46. 2',3'-Didehydro-3'-deoxy-4'-ethynylthymidine Derivatives for Treatment Infections Caused by Human Immunodeficiency Virus (HIV) Multidrug Resistant Strains, Method of Their Synthesis and Pharmaceutically Acceptable Forms of Drugs. Ziemkowski, P.a., A. Miazga, T. Kulikowski, S. Louvel, T. Klimkait, and V. Vidal. 2012: 2010-172853 2402358: 7pp.

[SciFinder]. HIV_0120-020212.